For example, tolcapone, the approved drug molecule for Parkinson’s disease, was shown to bind to TTR tetramer better than tafamidis and exhibit superior BBB permeability, thus being a strong therapeutic candidate for TTR amyloidosis [16,17]. This evidence concerns the gene TTR and Parkinson disease.